220 related articles for article (PubMed ID: 27648703)
1. MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Beppu T; Terasaki K; Sasaki T; Sato Y; Tomabechi M; Kato K; Sasaki M; Ogasawara K
Clin Nucl Med; 2016 Nov; 41(11):852-857. PubMed ID: 27648703
[TBL] [Abstract][Full Text] [Related]
2. Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.
Deuschl C; Moenninghoff C; Goericke S; Kirchner J; Köppen S; Binse I; Poeppel TD; Quick HH; Forsting M; Umutlu L; Herrmann K; Hense J; Schlamann M
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1285-1295. PubMed ID: 28258444
[TBL] [Abstract][Full Text] [Related]
3. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
4. Comparisons Between PET With 11C-Methyl-L-Methionine and Arterial Spin Labeling Perfusion Imaging in Recurrent Glioblastomas Treated With Bevacizumab.
Beppu T; Sato Y; Sasaki T; Terasaki K; Yamashita F; Sasaki M; Ogasawara K
Clin Nucl Med; 2019 Mar; 44(3):186-193. PubMed ID: 30562194
[TBL] [Abstract][Full Text] [Related]
5. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
6. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
8. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
9. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
[TBL] [Abstract][Full Text] [Related]
10. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis.
Ueda S; Saeki T; Osaki A; Yamane T; Kuji I
Clin Cancer Res; 2017 Oct; 23(19):5769-5778. PubMed ID: 28679773
[No Abstract] [Full Text] [Related]
12. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
17. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H
Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
19. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
[TBL] [Abstract][Full Text] [Related]
20. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
